Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiamulin fumarate is a semi-synthetic pleuromutilin antibiotic primarily utilized in veterinary medicine for the treatment of swine dysentery caused by Brachyspira hyodysenteriae and mycoplasmal pneumonia. It exerts its antimicrobial effect by binding to the peptidyl transferase center of the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis. Beyond its established antibiotic properties, recent high-throughput screening has identified tiamulin fumarate as a potential small-molecule inhibitor of Tumor Necrosis Factor-alpha (TNF-α). In preclinical models of psoriasis, it has demonstrated the ability to block NF-κB and MAPK signaling pathways, leading to improved dermatitis symptoms. This dual activity suggests potential for drug repositioning in human inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiamulin fumarate.